Annual report
2784.TEDINET S100W3KK
Period2024-04-01 → 2025-03-31
Filed2025-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.96T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.86T | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.61T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥38.1bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥38.5bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥40.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥31.9bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥39.4bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥43.8bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥27.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥24.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥27.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥29.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥1.44T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.45T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.30T | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.32T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥957.6bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥967.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥482.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥479.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥471.8bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥490.0bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥177.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥213.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥174.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥212.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥158.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥179.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥169.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥5.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥86.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥21.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥24.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥23.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥19.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥12.9bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥14.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥147.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.13 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,650.27 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,566.5 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,411.89 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,330.36 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,313.66 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 12,452 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 12,517 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 11,772 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 11,925 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 12,045 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥20.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.3bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥17.2bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥25.3bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥18.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥14.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥18.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.2bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥20.3bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥18.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥13.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥18.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥13.3bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥20.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥13.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥23.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥272.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥266.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥271.9bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥265.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥277.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥53.8bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥43.5bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥219.0bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥223.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥256.8bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥247.6bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥261.3bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥13.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥20.9bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥98.99 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥69.32 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥100.79 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.88 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.78 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥63 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥57 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥53 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,204.83 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,195.52 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,269.01 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,223.58 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,234.61 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 80.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.4% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 191,300,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 202,840,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 202,840,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 56 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 51 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 47 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 44 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 84
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥35.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥35.8bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥19.3bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | ¥183m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥14.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥7.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | employees | at 2025-03-31 | 9393 pure |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.64T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.62T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥19.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2025-03-31 | ¥1.24T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥33.1bn |
| Manufacturing Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.1bn |
| Manufacturing Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Manufacturing Businessreportable segment | employees | at 2025-03-31 | 1384 pure |
| Manufacturing Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥54.1bn |
| Manufacturing Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥37.7bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥16.4bn |
| Manufacturing Businessreportable segment | segment assets | at 2025-03-31 | ¥73.0bn |
| Manufacturing Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Medical Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥741m |
| Medical Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥376m |
| Medical Related Businessreportable segment | employees | at 2025-03-31 | 1131 pure |
| Medical Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥37.0bn |
| Medical Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥37.0bn |
| Medical Related Businessreportable segment | segment assets | at 2025-03-31 | ¥16.5bn |
| Medical Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥596m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥948m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥346m |
| Self Medication Products Wholesaling Businessreportable segment | employees | at 2025-03-31 | 395 pure |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥265.7bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥265.3bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥473m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2025-03-31 | ¥93.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥18.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥3.00T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.96T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥35.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.42T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥37.9bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥2.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥33.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥33.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥29.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | ¥78m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥22.5bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥6.2bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.54T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.52T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥18.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2024-03-31 | ¥1.24T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥33.1bn |
| Manufacturing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Manufacturing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.6bn |
| Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥52.7bn |
| Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥37.6bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥15.1bn |
| Manufacturing Businessreportable segment | segment assets | at 2024-03-31 | ¥67.4bn |
| Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Medical Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥559m |
| Medical Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥350m |
| Medical Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥36.7bn |
| Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥36.7bn |
| Medical Related Businessreportable segment | segment assets | at 2024-03-31 | ¥16.8bn |
| Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥713m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥254m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥364m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥262.8bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥262.3bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥498m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2024-03-31 | ¥94.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥25.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥2.89T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥2.86T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥33.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.42T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥38.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,181
| Item | Context | Value | Unit |
|---|---|---|---|
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row10Member | 0.714 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | 0.165 | |
| Regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | 0.250 | |
| Non regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | 0.769 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | 0.731 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | 0.875 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | 0.148 | |
| Regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | 0.583 | |
| Non regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | 0.692 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | 0.767 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | 0.717 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | 0.000 | |
| Regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | 0.000 | |
| Non regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | 0.920 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | 0.901 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | － | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | 0.151 | |
| Regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | 0.727 | |
| Non regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | 0.639 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | 0.686 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | 0.767 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row15Member | 0.238 | |
| Regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row15Member | 0.000 | |
| Non regular employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row15Member | － | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row15Member | 0.767 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row15Member | 0.722 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row15Member | 0.739 | |
| Research and development expenses research and development activities | CurrentYearDuration | 1896000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 12432000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 733000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000ManufacturingBusinessReportableSegmentsMember | 1930000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 562000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_ReportableSegmentsMember | 15659000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_UnallocatedAmountsAndEliminationMember | 807000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 16466000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 191300000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 191300000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 191300000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 191300000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 35 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 27 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 255 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 340 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 12 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |